Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
United Therapeutics ( (UTHR) ) has shared an update.
On March 30, 2026, United Therapeutics reported that its 598-patient phase 3 TETON-1 trial of nebulized Tyvaso in idiopathic pulmonary fibrosis met its primary endpoint, showing a 130.1 mL advantage in forced vital capacity over placebo at 52 weeks and reduced risk of clinical worsening, with consistent benefits across subgroups and no new safety signals. Integrated analyses of TETON-1 and TETON-2 confirmed significant treatment effects on lung function and key secondary outcomes, and the company said the unprecedented IPF data from TETON alongside its recent ralinepag success mark an inflection point for growth as it prepares an FDA filing to add IPF to Tyvaso’s label, potentially reshaping the treatment landscape for this underserved disease.
The most recent analyst rating on (UTHR) stock is a Hold with a $486.00 price target. To see the full list of analyst forecasts on United Therapeutics stock, see the UTHR Stock Forecast page.
Spark’s Take on UTHR Stock
According to Spark, TipRanks’ AI Analyst, UTHR is a Outperform.
The score is driven primarily by exceptional financial strength (high margins, strong cash generation, and debt eliminated) and supportive earnings-call fundamentals with meaningful pipeline catalysts. Offsetting factors are mixed near-term technical momentum, competitive/binary execution risk, and valuation support limited by the lack of a provided dividend yield.
To see Spark’s full report on UTHR stock, click here.
More about United Therapeutics
United Therapeutics Corp., a Nasdaq-listed public benefit corporation, develops therapies for rare cardiopulmonary and respiratory diseases, including pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Its portfolio features Tyvaso, a treprostinil-based inhalation therapy, and pipeline programs such as ralinepag targeting advanced cardiopulmonary indications.
Average Trading Volume: 438,973
Technical Sentiment Signal: Buy
Current Market Cap: $22.91B
Find detailed analytics on UTHR stock on TipRanks’ Stock Analysis page.